About Us
Nanophysics & Beyond
Curadigm
The Management
Our Commitments
Healthcare Professionals
Scientific Publications
Patients
Patient Engagement
Investors
Corporate Presentation
Financial Calendar
Regulated Information
SEC Filings
Annual General Meetings
Shareholder Corner
Press Releases
Congresses & Events
Nanotalks
NBTXR3 Development
R&D Day
Our Expert Videos
Nanoblog
From Curie to Nano
Contact & Newsletter
Medical Device Vigilance – Pharmacovigilance
Medical Information
Join Us
Nous vous informons que ce site est conforme à la législation française actuelle sur les dispositifs médicaux.
Continuer
Rester sur la page
Scientific Clinical | Nanobiotix announces publication of phase III soft tissue sarcoma data for first-in-class NBTXR3 in the Lancet Oncology
Corporate | Nanobiotix announces new organizational structure as the company enters its next stage after first european market approval
11 September 2019
Financial | Nanobiotix announces second quarter 2019 revenue
11 September 2019
Scientific Clinical | Nanobiotix announces publication of phase III soft tissue sarcoma data for first-in-class NBTXR3 in the Lancet Oncology
Published by
Julie Ficheux
on
11 September 2019
Test
No translations available for this page
